Nicholas B.
- Country
- Sweden
- Department
- Barnsjukhuset, SUH Lund
Research Overview
- Evaluation of Long-Term Safety of Oral Deucrictibant (PHA-022121) for Acute Hereditary Angioedema Attacks in C1-Inhibitor Deficient Patients
- Phase 3 Randomized Double-Blind Placebo-Controlled Crossover Study of Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks in Adolescents and Adults
Data & Insights
Has run more than one trial at 23 of 29 partner sites.
Specializations
Rare Genetic Disorders
This investigator specializes in the study of hereditary angioedema (HAE), focusing on innovative therapeutic approaches for managing this rare genetic condition.
- Type 1 and Type 2 C1-Inhibitor Deficiency
- Acute Angioedema Attack Management
- Laryngeal Attack Treatment
Their research encompasses breakthrough oral treatments for acute HAE episodes.
Therapeutic Innovation
The investigator's work centers on developing on-demand treatment solutions for patients experiencing acute angioedema attacks.
- Novel Oral Therapeutics
- Acute Attack Intervention
- Long-term Treatment Safety
Their research focuses on advancing oral medication options for HAE management.
Clinical Applications
The investigator evaluates therapeutic efficacy in both adolescent and adult populations affected by HAE.
- Symptom Relief Assessment
- Treatment Response Time
- Patient Safety Monitoring
Their work aims to establish effective protocols for acute HAE attack treatment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.